Kumis treatment in medical rehabilitation of patients with pneumonia associated with the novel coronavirus infection COVID-19

2021 ◽  
pp. 33-39
Author(s):  
Lira Talgatovna Gilmutdinova ◽  
Elvira Railevna Faizova ◽  
Aydar Rashitovich Gilmutdinov ◽  
Ruslan Ralifovich Garaev ◽  
Naufal Rabisovich Yanbukhtin ◽  
...  
Keyword(s):  
Well Being ◽  
Main Group ◽  
Medical Rehabilitation ◽  
Control Group ◽  
External Respiration ◽  
Forced Expiration ◽  
The Novel ◽  
Severity Of Depression ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The results of evaluating the effectiveness of the use of kumis treatment in 64 patients who have had pneumonia associated with the novel coronavirus infection COVID-19 are presented. It was found that the use of kumis treatment in addition to the basic complex in 32 patients of the main group has led to an increase in exercise tolerance by 13.6 % (p < 0,05), a decrease in the severity of shortness of breath by 36.3 % (p < 0.05), and contributed to the improvement of the parameters of the function of external respiration with an increase in the vital capacity of the lungs by 14,4 % (p < 0,05), the volume of forced expiration — by 24,5 % (p < 0,05). Against the background of kumis treatment, the patients of the main group showed a significant decrease in the severity of depression and anxiety — by 62.5 % (p < 0.05) and by 62.3 % (p < 0,05), respectively, an improvement in the parameters of «well-being» by 62,2 % (p < 0.05), «activity» — by 37,6 % (p < 0,05), «mood» — by 35,5 % (p < 0,05), compared to the initial values. The dynamics of parameters in the patients of the control group against the background of the basic complex turned out to be less significant in comparison with the main group.

Normoxic barotherapy in medical rehabilitation of patients after the novel coronavirus infection

2020 ◽  
pp. 29-35
Author(s):  
A. S. Kaisinova ◽  
A. N. Semukhin ◽  
A. V. Abramtsova ◽  
N. V. Efimenko ◽  
D. I. Velikanov ◽  
...  
Keyword(s):  
Rehabilitation Program ◽  
Medical Rehabilitation ◽  
Control Group ◽  
Spa Therapy ◽  
Blood Oxygen ◽  
The Novel ◽  
Physical And Mental Health ◽  
Blood Oxygen Saturation ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The purpose of the study is to develop a medical rehabilitation program for the patients who have come through a new coronavirus infection in the resort of Pyatigorsk. Material and methods. In the conditions of the health center named after S.M. Kirov in Pyatigorsk, a branch of FSBI NCFSCC FMBA of Russia, there have been observed 52 patients who had the new coronavirus infection COVID-19 of moderate severity, at the age from 18 up to 65 years old. Two groups have been formed by simple randomization: in the main group, the patients received normoxic barotherapy against the background of traditional spa therapy for pulmonary patients; in the control group, the patients had only conventional therapy. Results. The inclusion of normoxic barotherapy in the complex of medical rehabilitation of patients who came through the novel coronavirus infection contributed to the increase of tolerance to exercise and improved blood oxygen saturation in 92,9 % of cases, restoration of impaired functions of bronchopulmonary apparatus in 89,3 % and physical and mental health in 85.7 % of cases, which was significantly higher in comparison to similar indicators in the control group. Conclusion. Medical rehabilitation of patients after the new coronavirus infection in the resort is justified and advisable.

scholarly journals Rehabilitation after new coronavirus infection (COVID-19): principles and approaches

2021 ◽  
Vol 11 (4) ◽  
pp. 6-14
Author(s):  
Marina G. Bubnova ◽  
Anna L. Persiyanova-Dubrova ◽  
Nadezhda P. Lyamina ◽  
David M. Aronov
Keyword(s):  
Interpersonal Relationships ◽  
Rehabilitation Program ◽  
Medical Rehabilitation ◽  
The Novel ◽  
Multisystem Disease ◽  
Professional Activities ◽  
Rehabilitation Programs ◽  
Coronavirus Infection ◽  
Self Service ◽  
Novel Coronavirus

The novel coronavirus infection (COVID-19), which quickly became a pandemic in 2020, has presented new challenges for healthcare system. COVID-19, being a contagious infectious disease predominantly affects respiratory system, causes cardiovascular, neurocognitive, renal, gastrointestinal, hepatic, metabolic and mental damages, which is in fact a multisystem disease. Patients with COVID-19, primarily with moderate and severe forms, need appropriate rehabilitation. This article establishes need of development of rehabilitation programs for COVID-19 patients, identifies their problems that leads to restrictions on everyday life, self-service, mobility, communication, interpersonal relationships, and professional activities. Goals and general principles of medical rehabilitation in context of a pandemic at all three stages are presented. Features of rehabilitation approaches are highlighted and important components of individual rehabilitation program for COVID-19 patients are highlighted.

Analysis of the clinical manifestations of cerebral stroke in patients with the novel coronavirus infection (COVID-19)

2020 ◽  
pp. 30-45
Author(s):  
Vladislav V. Andreev ◽  
Alexander Y. Podunov ◽  
Daniil S. Lapin ◽  
Zarema L. Gilyaeva ◽  
Ekaterina N. Nikiforova ◽  
...  
Keyword(s):  
Lung Tissue ◽  
Hemorrhagic Stroke ◽  
Clinical Laboratory ◽  
Clinical Manifestations ◽  
Community Acquired Pneumonia ◽  
Control Group ◽  
Cerebral Stroke ◽  
The Novel ◽  
Coronavirus Infection ◽  
Novel Coronavirus

Objective: To improve the diagnosis and treatment of acute cerebrovascular accident in patients with community-acquired pneumonia caused by the novel coronavirus infection (COVID-19). Materials and methods: For the first time, clinical manifestations of strokes in patients with diagnosed new coronavirus infection (COVID-19) were analyzed in 130 patients. The study was conducted in two groups. The main group consisted of 69,2 % (n = 90) with a clinical and instrumental diagnosis: novel coronavirus infection in combination with stroke. The control group (30,8 %; n = 40) included the cases of ischemic and hemorrhagic stroke without signs of SARS-CoV-2. In both groups, the severity of the disease and pathogenetic subtypes were compared, and the features of the laboratory biochemical data were studied. Statistical analysis of the outcomes was carried out taking into account the severity of brain and lung tissue damage. Results: In patients with cerebral stroke against the background of the new coronavirus infection (COVID-19), the prevalence of ischemic stroke cases (86,4 %) was noted for undetermined (41,4 %) and cardioembolic (35,7 %) pathogenetic subtypes (according to TOAST) with localization in the carotid basin (89,7 %). In hemorrhagic stroke, parenchymal hemorrhage was observed with a greater frequency (54,5 %). The severity of the diagnosed strokes according to the NIHSS scale was up to 13,16 (8,80) points with less severe brain damage — Glasgow coma scale (14,0 (12,0 15,0). In the group of the patients, a widespread lesion of the lung tissue was diagnosed in 82,2 % of cases. No significant increase in the incidence of clinically significant manifestations of systemic and organ hypercoagulation was established. Conclusions: In stroke patients with COVID-19, ischemic manifestations with undetermined and cardioembolic subtypes without age and gender features prevail, with no differences in the severity of the course and a large number of favorable outcomes. A high activity of inflammatory and infectious changes was established by clinical laboratory.

scholarly journals Study of the effectiveness of methylprednisolone at different stages of inpatient care for patients with pneumonia caused by a new COVID-19 coronavirus infection

2020 ◽  
Author(s):  
EE Arinina ◽  
RT Tairova ◽  
AB Berdalin ◽  
SS Gujev ◽  
NA Glotova ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Inpatient Care ◽  
Brain Research ◽  
Medical Ward ◽  
Control Group ◽  
The Novel ◽  
Cytokine Storm ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Federal Center

Glucocorticoid therapy for a cytokine storm is one of the mainstays of managing the novel coronavirus disease COVID-19. The aim of this study was to evaluate the efficacy of methylprednisolone at different stages of medical care: in an intensive care unit (ICU) vs. a medical ward setting. Methylprednisolone therapy was delivered to 54 patients, amounting to 9% of the total patients hospitalized to the Federal Center of Brain Research and Neurotechnology of FMBA, Russia. Twenty-eight patients received methylprednisolone in the ICU setting; 26 patients, in a medical ward setting. The control group comprised 14 patients. Methylprednisolone was administered continuously, intravenously at 250 mg per day over the course of 3 days; the total dose was 750 mg. The analysis revealed a significant reduction in mortality in the group receiving methylprednisolone in a medical ward setting (7.7%) in comparison with the group receiving the drug in ICU (67.9%) and the control group (42.9%, р<0.001). The need for mechanical ventilation was lower in the group receiving methylprednisolone in a medical ward (2 (7.7%), 20 (71.4%) and 7 (50%) cases, respectively, р<0.001). Thus, preventive anti-inflammatory methylprednisolone therapy for delivered in a medical ward setting reduces hospital mortality and the need for MV in patients with COVID-19-induced pneumonia.

scholarly journals EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19)

2020 ◽  
Vol 8 (3) ◽  
pp. 150-159
Author(s):  
L. A. Balykova ◽  
V. F. Pavelkina ◽  
N. V. Shmyreva ◽  
N. A. Pyataev ◽  
N. M. Selezneva ◽  
...  
Keyword(s):  
Therapy Group ◽  
Drug Efficacy ◽  
Main Group ◽  
Ordinal Scale ◽  
The Novel ◽  
Efficacy And Safety ◽  
Standard Therapy Group ◽  
Moderate Severity ◽  
Coronavirus Infection ◽  
Novel Coronavirus

The aim of the study is to assess the efficacy and safety of the Favipiravir (Areplivir) drug, compared to the standard etiotropic therapy in the patients hospitalized with COVID-19.Material and methods. The research was conducted as a part of an open, randomized, multicenter comparative study of the efficacy and safety of Areplivir, 200 mg film-coated tablets (“PROMOMED RUS” LLC, Russia), in the patients hospitalized with COVID-19. The dosing regimen of Favipiravir was 1600 mg twice a day on the 1st day and 600 mg twice a day on days 2–14. Thirty nine patients were enrolled into the study with a laboratory-established diagnosis of a new type of Coronavirus infection caused by SARS-CoV-2 (confirmed) of moderate severity, with pneumonia. The group of comparison (22 patients) received standard etiotropic therapy, prescribed in accordance with the current version of the temporary guidelines for the diagnosis and treatment of COVID-19, represented mainly by Hydroxychloroquine with the dosage regimen of 800 mg on the 1st day, then 400 mg on days 2–7, and Azithromycin 500 mg once a day for 5 days. The main group (17 patients) received Favipiravir (Areplivir) as etiotropiс therapy.Results. In the main group, the time period until fever disappeared was found to be 1.36 days shorter than in the group of comparison (p<0.05); there was a higher rate of the reduction of inflammatory changes in the lungs according to the computer tomography data (38.4% vs 14.9%, p<0.05). By the end of the treatment, there was also a lower lactate level in the blood (27.1%, p<0.05) than in the patients of the group of comparison. The evaluation of the drug efficacy ассording to the Categorical Ordinal Scale of Clinical Improvement and measurements of oxygen saturation in the blood, manifested similar positive dynamics in the patients treated ассording to various etiotropic therapy regimens. By the end of the treatment, the RNA SARS-CoV-2 tests were also negative in all the patients. As for the overall frequency of adverse events (AEs), no relevant distinctions were found between the groups. A greater part of AEs was related to hepatotoxicity, with a predominantly clinically relevant increase in alanine aminotransferase (ALT). A clinically relevant prolongation of the corrected QT interval on the standard ECG was found to occur in the standard-therapy group on day 5, while no serious AEs were registered in the main group. No serious adverse reactions were registered in patients of the main group.Conclusion. The efficacy of the Favipiravir (Areplivir) therapy for the novel coronavirus infection has proved to be superior to the efficacy of the standard etiotropic therapy in a number of aspects. Basing on the obtained findings, Favipiravir (Areplivir) drug can be recommended for treating patients with the novel coronavirus infection of moderate severity.

Association and treatment of diabetes in patients affected by Covid-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1198-1201
Author(s):  
Syed Yasir Afaque
Keyword(s):  
Diabetes Mellitus ◽  
Prognostic Value ◽  
Heart Diseases ◽  
The Novel ◽  
The World ◽  
Treatment Of Diabetes ◽  
Coronavirus Infection ◽  
Composite Outcomes ◽  
Novel Coronavirus ◽  
The Impact

In December 2019, a unique coronavirus infection, SARS-CoV-2, was first identified in the province of Wuhan in China. Since then, it spread rapidly all over the world and has been responsible for a large number of morbidity and mortality among humans. According to a latest study, Diabetes mellitus, heart diseases, Hypertension etc. are being considered important risk factors for the development of this infection and is also associated with unfavorable outcomes in these patients. There is little evidence concerning the trail back of these patients possibly because of a small number of participants and people who experienced primary composite outcomes (such as admission in the ICU, usage of machine-driven ventilation or even fatality of these patients). Until now, there are no academic findings that have proven independent prognostic value of diabetes on death in the novel Coronavirus patients. However, there are several conjectures linking Diabetes with the impact as well as progression of COVID-19 in these patients. The aim of this review is to acknowledge about the association amongst Diabetes and the novel Coronavirus and the result of the infection in such patients.

Impact of Novel Coronavirus (COVID-19) on Pregnant Women: A Review

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Saima Habeeb ◽  
Manju Chugani
Keyword(s):  
Pregnant Women ◽  
Vertical Transmission ◽  
Respiratory Infections ◽  
Age Groups ◽  
Well Being ◽  
Fetal Outcome ◽  
Global Public Health ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
The Impact

: The novel coronavirus infection (COVID‐19) is a global public health emergency.Since its outbreak in Wuhan, China in December 2019, the infection has spread at an alarming rate across the globe and humans have been locked down to their countries, cities and homes. As of now, the virus has affected over 20million people globally and has inflicted over 7 lac deaths. Nevertheless, the recovery rate is improving with each passing day and over 14 million people have recuperated so far. The statistics indicate that nobody is immune to the disease as the virus continues to spread among all age groups; newborns to the elders, and all compartmentsincluding pregnant women. However, pregnant women may be more susceptible to this infection as they are, in general, highly vulnerable to respiratory infections. There is no evidence for vertical transmission of the COVID-19 virus among pregnant women, but an increased prevalence of preterm deliveries. Besides this, the COVID-19 may alter immune response at the maternal-fetal interface and affect the well-being of mothers as well as infants. Unfortunately, there is limited evidence available in the open literature regarding coronavirus infection during pregnancy and it now appears that certain pregnant women have infected during the present 2019-nCoV pandemic. In this short communication, we study the impact of the COVID-19 infection on vertical transmission and fetal outcome among pregnant women.

High cytokine levels and cytokine storm in the novel coronavirus infection

2021 ◽  
pp. 38-47
Author(s):  
Maksim Leonidovich Maksimov ◽  
Albina Ayratovna Zvegintseva ◽  
Lyudmila Yurievna Kulagina ◽  
Albina Zainutdinovna Nigmedzyanova ◽  
Elvina Ramisovna Kadyseva
Keyword(s):  
Peripheral Blood ◽  
High Frequency ◽  
The Novel ◽  
Cytokine Storm ◽  
The Public ◽  
Systemic Inflammatory Reaction ◽  
Scientific World ◽  
Cytokine Levels ◽  
Coronavirus Infection ◽  
Novel Coronavirus

A review article is based on current foreign sources. The level of cytokines in the peripheral blood can be increased in many diseases, but in some cases there may be an excess of their normal concentration in tens, hundreds or more times with the development of a peculiar clinical picture, which is based on a systemic inflammatory reaction. In the literature this condition has received the figurative name «cytokine storm», which highlights an extremely violent reaction of the immune system with an unknown (often unfavorable) outcome. Close attention of the scientific world and the public to the problem of extremely high levels of cytokines in the peripheral blood (hypercytokinemia) was drawn due to the high frequency of the cytokine storm in the novel coronavirus infection.

Sign in / Sign up

Export Citation Format

Share Document